Related Experiment Video
Updated: Aug 25, 2026
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Screening for neonatal endocrinopathies: rationale, methods and results
Guy Van Vliet1, Paul Czernichow
1Université de Montréal and Endocrinology Service, Hôpital Sainte-Justine, 3175 Côte Ste-Catherine, Montréal H3T 1C5, Québec, Canada. gvanvliet@justine.umontreal.ca
Insights
Newborn screening for congenital hypothyroidism and congenital adrenal hyperplasia using dried blood spots enables early diagnosis and treatment. This is crucial for preventing cognitive deficits and neonatal deaths, though challenges like false positives exist.
Area of Science:
- Neonatal screening
- Endocrinology
- Public health
Background:
- Congenital hypothyroidism and congenital adrenal hyperplasia require timely diagnosis to prevent severe health outcomes.
- Dried blood spot testing offers a method for early detection of these conditions in newborns.
- Screening programs aim to prevent mental deficiency and neonatal mortality.
Purpose of the Study:
- To highlight the importance of rapid turnaround times in newborn screening programs.
- To discuss the benefits of biochemical screening for congenital hypothyroidism and congenital adrenal hyperplasia.
- To address challenges associated with screening, such as false positives.
Main Methods:
- Measurement of thyrotropin or thyroxine from dried blood spots for congenital hypothyroidism.
- Measurement of 17-hydroxy-progesterone from dried blood spots for congenital adrenal hyperplasia.
- Analysis of screening program efficiency and diagnostic accuracy.
Main Results:
- Early diagnosis through dried blood spot testing prevents mental deficiency in congenital hypothyroidism.
- Screening for congenital adrenal hyperplasia prevents neonatal deaths, but clinical awareness is variable.
- Biochemical screening facilitates earlier treatment for both conditions.
Conclusions:
- Rapid screening is vital for preventing long-term cognitive issues in congenital hypothyroidism.
- While effective, screening for 21-hydroxylase deficiency faces challenges with false positives, impacting universal adoption.
- Dried blood spot analysis is a key tool in neonatal screening for endocrine disorders.
Abstract:
The measurement of thyrotropin or thyroxine from dried blood spots collected from neonates allows diagnosis before clinical manifestations develop, and prevents mental deficiency from congenital hypothyroidism. However, severely hypothyroid newborns remain at risk of cognitive problems that may be avoided if they are treated within two weeks of birth, hence the importance of a quick turnaround time of the screening programme. This also applies to screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency based on the measurement of 17-hydroxy-progesterone from dried blood; this was primarily designed to prevent neonatal deaths from acute adrenal insufficiency. This goal can be achieved by a high degree of clinical awareness of the diagnosis, but this has only been reported in a few jurisdictions. Furthermore, biochemical screening allows earlier treatment. On the other hand, there are many false positives, mostly in premature infants, so screening for 21-hydroxylase deficiency has not been universally adopted.
